𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma

✍ Scribed by Thomas Decaens; Alain Luciani; Emmanuel Itti; Anne Hulin; Françoise Roudot-Thoraval; Alexis Laurent; Elie Serge Zafrani; Ariane Mallat; Christophe Duvoux

Book ID
119230088
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
668 KB
Volume
44
Category
Article
ISSN
1590-8658

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of cetuximab in patients w
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
✍ Andrew X. Zhu; Keith Stuart; Lawrence S. Blaszkowsky; Alona Muzikansky; Donald P 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC). A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC. ## METHODS.

A phase II trial of gemcitabine in patie
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
✍ Charles S. Fuchs; Jeffrey W. Clark; David P. Ryan; Mathew H. Kulke; Haesook Kim; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract ## BACKGROUND There is no effective systemic therapy for patients with hepatocellular carcinoma. A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerabili